Literature DB >> 309306

CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterization.

A R English, J A Retsema, A E Girard, J E Lynch, W E Barth.   

Abstract

CP-45,899 {3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 4,4-dioxide, [2S-(2alpha,5alpha)]} is an irreversible inhibitor of several bacterial penicillinases and cephalosporinases. In the presence of low concentrations of CP-45,899, ampicillin and other beta-lactams readily inhibit the growth of a variety of resistant bacteria that contain beta-lactamases. CP-45,899 used alone displays only weak antibacterial activity, with the notable exception of its potent effects on susceptible and resistant strains of Neisseria gonorrhoeae. CP-45,899 appears to be somewhat less potent but markedly more stable (in aqueous solution) than the recently described beta-lactamase inhibitor clavulanic acid. The spectrum extensions provided by the two compounds are similar. A 1:1 mixture of CP-45,899 and ampicillin displays marked antimicrobial activity in mice experimentally infected with ampicillin-resistant Staphylococcus aureus, Haemophilus influenzae, Klebsiella pneumoniae, and Proteus vulgaris.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 309306      PMCID: PMC352474          DOI: 10.1128/AAC.14.3.414

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

1.  Micro-iodometric assay for penicillinase.

Authors:  R P NOVICK
Journal:  Biochem J       Date:  1962-05       Impact factor: 3.857

2.  Clavulanic acid: a beta-lactamase-inhiting beta-lactam from Streptomyces clavuligerus.

Authors:  C Reading; M Cole
Journal:  Antimicrob Agents Chemother       Date:  1977-05       Impact factor: 5.191

3.  Naturally-occurring beta-lactamase inhibitors with antibacterial activity.

Authors:  A G Brown; D Butterworth; M Cole; G Hanscomb; J D Hood; C Reading; G N Rolinson
Journal:  J Antibiot (Tokyo)       Date:  1976-06       Impact factor: 2.649

4.  Effects of beta-lactamase from gram-negative organisms on cephalosporins and penicillins.

Authors:  C H O'Callaghan; P W Muggleton; G W Ross
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1968

Review 5.  The beta-lactamases of gram-negative bacteria and their role in resistance to beta-lactam antibiotics.

Authors:  R B Sykes; M Matthew
Journal:  J Antimicrob Chemother       Date:  1976-06       Impact factor: 5.790

  5 in total
  90 in total

1.  Concentrations of ampicillin and sulbactam in serum and tissues of patients undergoing ENT surgery.

Authors:  A Wildfeuer; H Luckhaupt; M Springsklee
Journal:  Infection       Date:  1991 Jan-Feb       Impact factor: 3.553

2.  Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis.

Authors:  R A Blum; R K Kohli; N J Harrison; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

3.  In vitro activities of cefoperazone and sulbactam singly and in combination against cefoperazone-resistant members of the family Enterobacteriaceae and nonfermenters.

Authors:  R J Fass; W W Gregory; R F D'Amato; J M Matsen; D N Wright; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

4.  In vitro evaluations of aminopenicillin/beta-lactamase inhibitor combinations.

Authors:  R N Jones
Journal:  Drugs       Date:  1988       Impact factor: 9.546

5.  Sulbactam/ampicillin versus cefotaxime as initial therapy in serious soft tissue, joint and bone infections.

Authors:  L Löffler; A Bauernfeind; W Keyl
Journal:  Drugs       Date:  1988       Impact factor: 9.546

6.  The inhibition of beta-lactamases from gram-negative bacteria by clavulanic acid.

Authors:  C Reading; T Farmer
Journal:  Biochem J       Date:  1981-12-01       Impact factor: 3.857

7.  Comparative inhibition beta-lactamases by novel beta-lactam compounds.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

8.  Antibacterial activity and kill kinetics of ampicillin/sulbactam (CP-45899) combinations against Escherichia coli and Klebsiella aerogenes.

Authors:  J E Fuglesang; T Bergan
Journal:  Infection       Date:  1984 Jan-Feb       Impact factor: 3.553

9.  Pharmacokinetics of sultamicillin in mice, rats, and dogs.

Authors:  A R English; D Girard; S L Haskell
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

10.  Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis.

Authors:  D P Reitberg; D A Marble; R W Schultz; T J Whall; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.